Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 14/20 | 0.52 |
| ▸ | MAOA | P21397 | 12/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754234 | 1.00 | CA9 (0.57) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL17081007 | 0.87 | CA9 (0.54) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL19376194 | 0.86 | MAOA (0.51) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL17969088 | 0.84 | CA9 (0.59) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL29746650 | 0.84 | AHR (0.56) | CA9MAOBCRBNSMYD3 | |
| SCHEMBL2811609 | 0.84 | AHR (0.56) | CA9MAOBCRBNSMYD3 | |
| SCHEMBL17080921 | 0.84 | MAOB (0.53) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL18944246 | 0.83 | MAOB (0.52) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL13156609 | 0.83 | CA9 (0.62) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL14843503 | 0.83 | CA9 (0.57) | CA9MAOBMAOANPC1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436955-A | Tetrahydroquinoline and benzomorpholine derivatives or salts thereof, and preparation method and application thereof | 复旦大学 | 2022-05-06 | — | — | CN | disclosed |
| US-10604532-B2 | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| EP-2763982-B1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | Bayer Pharma AG (DE) | 2018-01-10 | — | — | EP | disclosed |
| US-20170260198-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-09-14 | — | — | US | disclosed |
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
| US-9265763-B2 | — | — | 2016-02-23 | — | — | US | disclosed |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| EP-2763982-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | Bayer Pharma Aktiengesellschaft (DE) | 2014-08-13 | — | — | EP | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | CA9 4203/4885MAOB 374/4885MAOA 258/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CA9 484/4885MAOB 43/4885MAOA 85/4885 |
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | DRD4, DRD2, DRD3 | CA9 4264/4885MAOB 108/4885MAOA 211/4885 |
| US-10604532-B2 | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | BUB1, BUB1B, BUB3 | CA9 4297/4885MAOB 3504/4885MAOA 4251/4885 |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | CA9 4286/4885MAOB 3539/4885MAOA 4272/4885 |
| US-20170260198-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | CA9 4230/4885MAOB 3644/4885MAOA 4274/4885 |
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | CA9 4297/4885MAOB 3504/4885MAOA 4251/4885 |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BUB1, BUB1B, BUB3 | CA9 4297/4885MAOB 3504/4885MAOA 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.